Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MGAT4 family member F, pseudogene (MGAT4FP) is a non-protein coding transcript homologous to glycosyltransferases of the MGAT4 gene family, lacking a functional open reading frame[1][3]. In breast cancer, MGAT4FP is overexpressed, correlating strongly with poor prognosis and advanced tumor stage[1]. Experimental data suggest it acts in part as a competing endogenous RNA (ceRNA) by interacting with microRNAs and regulatory proteins to modulate gene expression of functional homologs and oncogenic transcription factors such as FOXM1[1][4]. Silencing MGAT4FP in breast cancer cell lines increases apoptosis and inhibits cell migration and tumor progression, particularly affecting key genes in the focal adhesion pathway[1]. There is currently no evidence for direct protein product, drug targeting, or utility in other disease areas, but its role as a biomarker and regulator of cancer biology has been validated[1][4]. The precise biological mechanisms and therapeutic utility remain the subject of ongoing research.
Not applicable; no drugs known to act directly. If targetable, it would involve knockdown strategies (siRNA/shRNA)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MGAT4 family member F, pseudogene (MGAT4FP).